Call to remove IP clauses from trade pact

Regional Comprehensive Economic Partnership (RCEP) deal could hit supply of cheap Indian drugs

August 16, 2016 01:51 am | Updated 01:51 am IST - New Delhi

As the next round of Regional Comprehensive Economic Partnership (RCEP) trade talks begin in Vietnam on Monday, humanitarian aid organisation Médecins Sans Frontières (MSF) has called for the removal of intellectual property provisions — known as the TRIPS-plus provisions — from the agreement. The talks are scheduled for August 15-19.

According to the MSF, the TRIPS-plus provisions like patent term extensions and data exclusivity could hinder access to affordable drugs.

The RCEP is a trade agreement being negotiated between the 10 Association of Southeast Asian Nations countries, and Australia, China, India, Japan, New Zealand and South Korea. The RCEP countries are home to nearly half the world’s population, including some of the most marginalised communities living in the three least-developed countries taking part in the trade negotiations, said Paul Lhungdim, President, Delhi Network of Positive People.

Nearly two-thirds of all the drugs MSF purchases to treat HIV, TB and malaria across the world are generic medicines from India; data exclusivity provisions under RCEP could delay the entry of generic medicines, according to Leena Menghaney, South Asia head, MSF Access Campaign.

Top News Today


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.